34551-41-2

Basic information

• Product Name: 5-BROMO-1-CHLOROISOQUINOLINE
• Synonyms: 5-BROMO-1-CHLOROISOQUINOLINE;1-Chloro-5-bromoisoquinoline;5-broMo-1-chloroisoquinolin;5-Bromo-1-chloro-2-azanaphthalene
• CAS NO: 34551-41-2
• Molecular Formula: C₉H₅BrClN
• Molecular Weight: 242.4997
• EINECS: -0
• Mol File: 34551-41-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 349.5 °C at 760 mmHg
• Flash Point: 165.2 °C
• Appearance: /
• Density: 1.673
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.06±0.43(Predicted)
• CAS DataBase Reference: 5-BROMO-1-CHLOROISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1-CHLOROISOQUINOLINE(34551-41-2)
• EPA Substance Registry System: 5-BROMO-1-CHLOROISOQUINOLINE(34551-41-2)

Safety Data

• Hazardous Substances Data: 34551-41-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-1-chloroisoquinoline is a chemical compound with the molecular formula C9H5BrClN. It is a heterocyclic aromatic compound that contains both a bromine and a chlorine atom attached to an isoquinoline ring. 5-BROMO-1-CHLOROISOQUINOLINE is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable tool in organic synthesis, particularly in the development of new drugs and crop protection products. Additionally, 5-Bromo-1-chloroisoquinoline has also been studied for its potential anti-cancer and anti-microbial properties, making it a versatile and important compound in various fields of research and industry.

Upstream product

• 223671-17-8 5-bromoisoquinolin-2-ium-2-olate 
• 34784-04-8 5-bromoisoquinoline 

Downstream Products

• 852570-80-0 5-bromoisoquinolin-1-ylamine 
• 852570-81-1 5-bromo-1-(quinolin-6-yl)aminoisoquinoline 
• 215453-51-3 7-bromo-1-chloroisoquinoline 
• 919363-10-3 5-bromo-N-(3-(dimethylamino)propyl)isoquinolin-1-amine 
• 374555-40-5 (5-bromo-isoquinolin-1-yl)-[6-(2-methylpyridine-3-yloxy)pyridin-3-yl]amine 
• 374555-37-0 (5-bromoisoquinolin-1-yl)-[3-(pyrimidin-5-yl)phenyl]amine 
• 374555-35-8 (5-bromoisoquinolin-1-yl)-[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]amine 
• 374555-34-7 (5-bromoisoquinolin-1-yl)-[3-(imidazol-1-yl)phenyl]amine 

Relevant articles and documents

Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases

One effective means to achieve inhibitor specificity for RAF kinases, an important family of cancer drug targets, has been to target the monomeric inactive state conformation of the kinase domain, which, unlike most other kinases, can accommodate sulfonamide-containing drugs such as vemurafenib and dabrafenib because of the presence of a unique pocket specific to inactive RAF kinases. We previously reported an alternate strategy whereby rigidification of a nonselective pyrazolo[3,4-d]pyrimidine-based inhibitor through ring closure afforded moderate but appreciable increases in selectivity for RAF kinases. Here, we show that a further application of the rigidification strategy to a different pyrazolopyrimidine-based scaffold dramatically improved selectivity for RAF kinases. Crystal structure analysis confirmed our inhibitor design hypothesis revealing that 2l engages an active-like state conformation of BRAF normally associated with poorly discriminating inhibitors. When screened against a panel of distinct cancer cell lines, the optimized inhibitor 2l primarily inhibited the proliferation of the expected BRAFV600E-harboring cell lines consistent with its kinome selectivity profile. These results suggest that rigidification could be a general and powerful strategy for enhancing inhibitor selectivity against protein kinases, which may open up therapeutic opportunities not afforded by other approaches.

BRIDGED BICYCLIC KALLIKREIN INHIBITORS

Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.

NOVEL BICYCLIC COMPOUND OR SALT THEREOF

Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are the same or different and each represent C—R2; any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are the same or different and each represent CH or N;R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O;R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.;R3 represents a hydrogen atom, —CO—R5 etc.;R4 represents a hydrogen atom, —CO—R6, —N(R7)(R8) etc.;R5 represents a hydroxyl group, an amino group etc.;R6 represents a hydroxyl group etc.;R7 and R8 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; and R9 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms etc.